Primary Immune Deficiency - Epidemiology Forecast to 2027

Primary Immune Deficiency - Epidemiology Forecast to 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

50

Choose License

Final Price

DelveInsight's "Primary Immune Deficiency (PID) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Primary Immune Deficiency (PID) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Primary Immune Deficiency (PID) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Primary Immune Deficiency (PID) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Primary Immune Deficiency (PID) outlook. It also includes the explanation of changing trends of epidemiology outlining the Primary Immune Deficiency (PID) scenario.

Primary Immune Deficiency (PID) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Primary Immune Deficiency (PID) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Primary Immune Deficiency (PID) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Primary Immune Deficiency (PID) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Primary Immune Deficiency (PID)

Key assessments
• Patient Segmentation in Primary Immune Deficiency (PID)
• Primary Immune Deficiency (PID) Risk & Burden
• Factors driving growth in a specific Primary Immune Deficiency (PID) patient population
1. Report Introduction
2. Primary Immune Deficiency (PID) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Primary Immune Deficiency (PID) in 2017
2.2. Patient Share Distribution of Primary Immune Deficiency (PID) in 2027
3. Disease Background and Overview: Primary Immune Deficiency (PID)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Primary Immune Deficiency (PID) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Primary Immune Deficiency (PID) in 7MM – By Countries
5. Epidemiology of Primary Immune Deficiency (PID) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.1.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.1.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.1.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.4.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.4.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.4.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.5.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.5.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.5.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.6.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.6.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.6.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.7.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.7.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.7.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.8.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.8.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.8.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Primary Immune Deficiency (PID)
5.9.3. Sub-Type Specific cases of the Primary Immune Deficiency (PID) *
5.9.4. Sex- Specific Cases of the Primary Immune Deficiency (PID) *
5.9.5. Diagnosed Cases of the Primary Immune Deficiency (PID)
6. Unmet Needs of the Primary Immune Deficiency (PID)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)*
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2027) *
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2027) *
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2027) *
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us